通利大肠对慢性阻塞性肺疾病大鼠外周血T淋巴细胞亚群的影响

目的:观察"通利大肠"对慢性阻塞性肺疾病(COPD)模型大鼠的外周血T淋巴细胞亚群的影响,从炎症调控角度探讨COPD"从肠论治"的效应机制。方法:用气管注射脂多糖加熏香烟联合造模方法建立COPD大鼠模型,宣白承气汤及其拆方作为实验用药随机分为正常组、模型组、治肠组、治肺组及肺肠同治组。正常组、模型组灌胃纯净水,各给药组灌胃相应中药,连续14d。流式细胞检测法检测外周血T淋巴细胞总数、辅助性T淋巴细胞(CD+3CD+4细胞)百分比、细胞毒性T淋巴细胞(CD+3CD+8细胞)百分比以及CD+4/CD+8水平。结果:与正常组比较,模型组大鼠T淋巴细胞总数减少,CD+3/CD+8升高,CD+4/CD+8水平降低(P0.01),CD+3/CD+4有降低的趋势。与模型组比较,治肠组CD+4/CD8+升高(P0.05)。与治肺组比较,肺肠同治组的T淋巴细胞总数增加,CD+4/CD8+升高(P0.05)。结论:通利大肠,或在治肺的基础上增加通利大肠,可影响COPD模型大鼠外周血T淋巴细胞的亚群分布,减少CD3+CD+8细胞的百分比,调节T淋巴细胞总数和CD3+CD+4细胞与CD+3CD+8细胞比例,这可能是COPD"从肠论治"效应产生的作用环节之一。

Effects of catharsis large intestine on T lymphocyte subsets in peripheral blood from rats with COPD

Objective: To observe the influence of ’catharsis large intestine’ on T lymphocyte subsets in peripheral blood from rats with COPD,and to investigate the mechanism of ’treating from intestine’.Methods: The rat model of COPD was established by cigarette smoking combined with intratracheal injection of LPS.All rats were randomly divided into normal control group,model group,treating lung group,treating intestine group,treating lung and intestine group.The normal control group,model group were intragastrically given the pure water,and other groups were intragastrically given corresponding herbal drugs for 14 days.The lymphocyte subsets in peripheral blood from all groups of 40 rats were measured via direct immunofluorescent assay by flow cytometry.The lymphocyte subsets include total T cells,CD3+ CD4+(Th cells)%,CD3+ CD8+(Tc cells)%,CD4+ /CD8+.Results: The amount of total T cells was markedly lower,while CD3+ CD8+ % was higher(P<0.01=,and CD4+ /CD8+ was decreased in the model group,compared with those in the normal control group.Compared with the model group,CD4+ /CD8+ level was higher in treating intestine group(P<0.05).Total T cells and CD4+ /CD8+ level were both increased in the lung-intestine treating group than those in the treating lung group.Conclusion: ’catharsis large intestine’ can decrease Tc cells and enhance the number of serum T cells and affect the balance of CD4+ and CD8+.